GLAUKOS CORP (GKOS) Stock Price, Forecast & Analysis
USA - New York Stock Exchange - NYSE:GKOS - US3773221029 - Common Stock
GKOS Key Statistics, Chart & Performance
The current stock price of GKOS is 108.72 USD. In the past month the price increased by 20.95%. In the past year, price decreased by -21.74%.
GKOS Latest News, Press Relases and Analysis
GKOS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 24.56 | 213.10B | ||
| ISRG | INTUITIVE SURGICAL INC | 64.57 | 197.07B | ||
| BSX | BOSTON SCIENTIFIC CORP | 31.42 | 137.42B | ||
| SYK | STRYKER CORP | 26.86 | 135.30B | ||
| IDXX | IDEXX LABORATORIES INC | 55.66 | 56.04B | ||
| BDX | BECTON DICKINSON AND CO | 13.76 | 56.63B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.65 | 48.70B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 18.4 | 38.48B | ||
| RMD | RESMED INC | 25.4 | 36.71B | ||
| DXCM | DEXCOM INC | 36.32 | 26.35B | ||
| PODD | INSULET CORP | 64.59 | 20.77B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.51 | 18.45B |
Related stock screener links
About GKOS
Company Profile
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company is headquartered in Aliso Viejo, California and currently employs 995 full-time employees. The company went IPO on 2015-06-25. The firm is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.
Company Info
GLAUKOS CORP
1 Glaukos Way
Aliso Viejo CALIFORNIA 92672 US
CEO: Thomas W. Burns
Employees: 995
Phone: 19493679600
GLAUKOS CORP / GKOS FAQ
Can you describe the business of GLAUKOS CORP?
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company is headquartered in Aliso Viejo, California and currently employs 995 full-time employees. The company went IPO on 2015-06-25. The firm is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.
What is the stock price of GLAUKOS CORP today?
The current stock price of GKOS is 108.72 USD. The price increased by 1.73% in the last trading session.
Does GLAUKOS CORP pay dividends?
GKOS does not pay a dividend.
What is the ChartMill technical and fundamental rating of GKOS stock?
GKOS has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the growth outlook for GLAUKOS CORP?
The Revenue of GLAUKOS CORP (GKOS) is expected to grow by 30.18% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of GKOS stock?
GLAUKOS CORP (GKOS) has a market capitalization of 6.24B USD. This makes GKOS a Mid Cap stock.
GKOS Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to GKOS. When comparing the yearly performance of all stocks, GKOS turns out to be only a medium performer in the overall market: it outperformed 59.33% of all stocks.
GKOS Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to GKOS. While GKOS seems to be doing ok healthwise, there are quite some concerns on its profitability.
GKOS Financial Highlights
Over the last trailing twelve months GKOS reported a non-GAAP Earnings per Share(EPS) of -1.02. The EPS increased by 52.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -8.77% | ||
| ROE | -11.39% | ||
| Debt/Equity | 0.09 |
GKOS Forecast & Estimates
22 analysts have analysed GKOS and the average price target is 121.53 USD. This implies a price increase of 11.78% is expected in the next year compared to the current price of 108.72.
For the next year, analysts expect an EPS growth of 55.55% and a revenue growth 30.18% for GKOS